key: cord-0708680-3privz6q
authors: Belli, Luca Saverio; Duvoux, Christophe; Cortesi, Paolo Angelo; Facchetti, Rita; Iacob, Speranta; Perricone, Giovanni; Radenne, Sylvie; Conti, Sara; Patrono, Damiano; Berlakovich, Gabriela; Hann, Angus; Pasulo, Luisa; Castells, Lluis; Faitot, Francois; Detry, Olivier; Invernizzi, Federica; Magini, Giulia; De Simone, Paolo; Kounis, Ilias; Morelli, Maria Cristina; Díaz Fontenla, Fernando; Ericzon, Bo-Göran; Loinaz, Carmelo; Johnston, Chris; Gheorghe, Liliana; Lesurtel, Mickael; Romagnoli, Renato; Kollmann, Dagmar; Perera, M Thamara PR; Fagiuoli, Stefano; Mirza, Darius; Coilly, Audrey; Toso, Christian; Zieniewicz, Krzysztof; Elkrief, Laure; Karam, Vincent; Adam, Rene; den Hoed, Caroline; Merli, Marco; Puoti, Massimo; De Carlis, Luciano; Oniscu, Gabriel C; Piano, Salvatore; Angeli, Paolo; Fondevila, Constantino; Polak, Wojciech G
title: COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
date: 2021-07-19
journal: Gut
DOI: 10.1136/gutjnl-2021-324879
sha: 5b7e8631fe6af4be92dd4f1310b95fa3ea115731
doc_id: 708680
cord_uid: 3privz6q

OBJECTIVE: Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. DESIGN: Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. RESULTS: From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170). CONCLUSIONS: Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

Patients with cirrhosis are at increased risk of infections and associated complications due to cirrhosisassociated immune dysfunction, [1] [2] [3] [4] with bacterial infections being the most frequent trigger of acute decompensation (AD) and acute-on-chronic liver failure (ACLF). 5 6 Existing evidence indicates the possibility that viral infections may cause AD and ACLF. 7 Although data on the role of SARS-CoV-2 are limited, SARS-CoV-2 is particularly feared for patients with decompensated cirrhosis (DC) on the waiting list (WL) for liver transplantation (LT), as ACLF may lead to early death if patients cannot be transplanted in due time. 8 Furthermore, the impact of SARS-CoV-2 infection on patients being transplanted after recovering from SARS-CoV-2 is relatively unknown. Thus, the European Liver and Intestine Association (ELITA) and the European Liver Transplant Registry (ELTR) called for a prospective registry aiming to address the following issues: 1. What is the mortality risk of COVID-19 in LT candidates and which are the determinants of death on clinical presentation? 2. How frequently does COVID-19 trigger ACLF, thus increasing the urgency for LT after recovering from COVID-19? Conversely, how many Hepatology patients developed severe respiratory failure and were removed from the WL? 3. What is the post-LT course of patients with pre-LT COVID-19? 4. Did clinical presentation and course of COVID-19 differ between the two waves of the pandemic?

ELITA/ELTR COVID-19 registry was circulated in February 2020 among 149 LT centres affiliated to ELTR and located in 30 European countries. All centres reporting at least one case were provided with a database and instructions on how to record structured data. Thirty-three centres responded having observed SARS-CoV-2 infection in adult LT candidates from 21 February to 20 November 2020. Inclusion criteria include adult patients listed for LT, patients presenting with symptoms consistent with SARS-CoV-2 infection and confirmation of SARS-CoV-2 infection by a positive result on a reverse-transcriptase PCR (RT-PCR) assay of a specimen collected on a nasopharyngeal swab or on bronchoalveolar lavage.

Exclusion criteria include patients with RT-PCR-confirmed SARS-CoV-2 infection without symptoms.

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.

Demographic and clinical data, including clinical symptoms or signs on presentation, laboratory and radiological results during COVID-19 management, administered antiviral therapies and antithrombotic prophylaxis were retrospectively collected. All laboratory tests and radiological assessments were performed on the discretion of the treating physician. Serum creatinine was converted to milligram per decilitre for analysis. Obesity was defined as a Body Mass Index of >30 kg/m 2 . Model for Endstage Liver Disease (MELD) score stands for pure Laboratory Model for End-stage Liver Disease (Lab-MELD) score without additional points. Dyspnoea at admission was considered when combined with O 2 saturation below 95. AD was defined as including one or more among the following events: de novo or worsening ascites, new or worsening hepatic encephalopathy, bacterial infection and/or variceal haemorrhage. The EASL Chronic Liver Failure Consortium (CLIF-C) definitions were used to determine the presence of ACLF in patients with AD and to calculate the CLIF-C-OF score and the CLIF-C ACLF score. 8 The submitted files from each centre were manually reviewed to assess for data quality, completeness and inconsistencies. In addition, submitting clinicians were contacted and asked to provide corrections or data integration whenever needed.

To understand the relative impact of COVID-19 on survival of cirrhotic patients listed for LT, a comparison was made with a control group of 91 cirrhotic patients hospitalised in 2016-2020 for AD triggered by bacterial infection. This control group was also used to evaluate the impact of COVID-19 on liver function deterioration related to ACLF development and associated mortality.

Data were collected in accordance with General Data Protection Regulation, the European Union legislation and the ELTR privacy policy.

Analysis was led by the Research Centre on Public Health, University of Milan-Bicocca, Monza, Italy. A descriptive analysis of the cohort was carried out on the overall population and following stratification of the population by site of management, at home, in general wards and in intensive care units (ICU). Categorical variables were summarised through percentages, and continuous variables through median, first quartile and third quartile. Categorical variables were compared using the χ 2 or Fisher's exact test; continuous variables were compared using the Mann-Whitney U-test or the Kruskall-Wallis test, when appropriate. All tests were two-sided and used a significance level of 0.05.

Cumulative incidence curves for LT from WL were constructed considering death as a competing risk. 9 The association between mortality and baseline clinically relevant characteristics of symptomatic patients were evaluated through univariate Cox proportional hazard models. All characteristics analysed in the univariate model were included in a stepwise selection process that identified the best multivariate model.

What is already known on this subject? ► Many publications have explored the impact of COVID-19 on patients with chronic liver disease, but no study has focused on patients on the waitlist for liver transplantation (LT).

What are the new findings? ► LT candidates with COVID-19 were at high risk of early death (32.7%), reaching 49.2% in those with decompensated cirrhosis (DC) and Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15, which is triple the mortality risk observed in listed patients with comparable Lab-MELD scores without COVID-19. ► The evaluation of two simple variables, Model for End-stage Liver Disease (MELD) class of ≥15 or <15 and dyspnoea (present or absent), allowed a clear distinction between the individual mortality risks on clinical presentation. ► Respiratory failure frequently resulted in LT candidate ineligibility for LT and was the most frequent cause of death. ► During the two waves of the pandemic, clinical presentation, course and mortality risk of COVID-19 did not significantly change. ► Short-term survival after LT was 96%, and no cases of SARS-CoV-2 reinfection were observed to date.

► LT candidates with DC should rigorously adopt all the usual measures to prevent SARS-CoV-2 infection and reinforced vaccination programmes should be implemented as the efficacy of standard vaccines is much lower than that reported in the registration studies. ► The evaluation of lab-MELD score and dyspnoea at clinical presentation will aid clinicians in their decision-making. ► LT in patients with prior COVID-19 is encouraged.

To compare the effect of COVID-19 or bacterial infection on risk of death, Cox proportional hazard models were performed after adjusting for MELD or Child-Pugh, and age, sex, aetiology and diabetes mellitus.

A further analysis was conducted to compare the patient characteristics and outcomes of LT candidates infected during the two waves of the pandemic. The end of the first wave (June 2020) and the beginning of the second wave (July 2020) were identified analysing the graphical trend in the number of new patients with COVID-19 reported in the registry. Overall survival of all patients was also provided. All statistical analyses were conducted using SAS V.9.4 and R V.4.0.0 (R Core Team, Vienna, Austria). The map was drawn using QGIS software V.3.10 (QGIS Development Team).

Thirty-three centres from 11 European countries observed at least one LT candidate with RT-PCR-confirmed SARS-CoV-2 infection. Of the 1865 patients on the WL at the participating sites, 136 LT candidates with SARS-CoV-2 infection (7.29%) were consecutively reported in the registry. Twenty-three (16.9%) were asymptomatic at the time of diagnosis, with the RT-PCR test being performed due to surveillance protocols for being in contact with a SARS-CoV-2-positive subject (13 cases), for screening at the time of LT (8 cases) and for screening at hospital admission for cirrhosis complications (2 cases). On comparing the baseline characteristics of the two groups of symptomatic and asymptomatic cases, no major significant differences emerged between the two populations (online supplemental table 1). These 23 asymptomatic cases were excluded for the analysis and their outcome is reported in online supplemental figure 1. The remaining 113 subjects (113/136, 83.1%), representing the 6.05% of the subjects on the WL, presented with symptomatic SARS-CoV-2 infection (COVID-19) and were analysed (figure 1 and online supplemental figure 2).

Thirty-three patients (29.2%) received homecare, and the remaining 80 patients (70.8%) required hospitalisation (figure 1), with 52 (65%) patients being treated in a general ward and 28 (35%) in the ICU. Baseline patient characteristics are reported in table 1. The median age was 58.0 (IQR 53-63) and 61.9% were men. DC with or without hepatocellular carcinoma (HCC) (68.1%) and HCC on compensated cirrhosis (17.7%) were the main indications for LT. 

Forty-five (39.8%) patients had diabetes mellitus; 26 (23.2%) had arterial hypertension; 12 (10.7%) had renal function impairment with serum creatinine of >2 mg/dL; and 5 (4.5%) had chronic obstructive lung diseases. Eighty-four (74.3%) patients had at least one comorbidity and 38 (33.6%) patients had two or more (table 1) .

At diagnosis, the most common symptoms included fever (74 patients, 65.5%), cough (64 patients, 56.6%) and dyspnoea (30 patients, 26.6%). Radiological imaging (CT scan or chest X-ray) showed typical ground-glass opacities in 61 cases (54%) (table 2), with bacterial pneumonia being superimposed in onethird of the cases (20/61=32.7%).

Overall, 56 (49.6%) patients required respiratory support during hospitalisation, with 13 requiring non-invasive ventilation and 15 requiring,invasive mechanical ventilation. Forty-nine patients received specific anti-SARS-CoV-2 treatment based on local protocols. Twenty-nine patients (25.7%) were treated with low-molecular weight heparin. Two patients experienced pulmonary thromboembolism; neither was on heparin prophylaxis.

Clinical features and outcomes in patients treated at home, in general wards and in the ICU Baseline characteristics and disease course of patients with less severe symptoms who could be treated at home and of those with more severe symptoms requiring hospitalisation in general wards and in ICU are reported in online supplemental table 2 and 3. Patients treated at home had lower Child-Pugh and 

Thirty-seven patients died (37/113, 32.7%) after a median of 18 (IQR 10-30) days from diagnosis, the great majority ( figure 7 ).

Twenty-six patients underwent an LT after a median interval of 78.5 (IQR 44-102) days from diagnosis (table 2) . Before being reactivated on the WL, all patients had to be asymptomatic and with a minimum of one negative RT-PCR rhinopharyngeal swab. An additional negative swab at the time of LT was required by all centres. Overall, the median ICU and hospital stay were 3 (IQR 3-6) and 11 (IQR 8-19 ) days, respectively. Immunosuppression included a calcineurin inhibitor drug in all patients (24 tacrolimus and 2 cyclosporine), with mycophenolate-mofetil being used in 21 cases. Survival rate was 96% at a median follow-up of 118 days (IQR 31-170), with a single patient dying from posterior reversible encephalopathy syndrome 82 days after LT.

This study reports on the first large cohort of patients who developed COVID-19 while listed for LT, and several novel findings regarding pretransplant and post-transplant outcomes were obtained, which are summarised as follows: LT candidates with symptomatic SARS-CoV-2 infection were at high risk of early death, particularly those with DC and Lab-MELD score of ≥15. The mortality risk was dramatically increased in patients with a Lab-MELD score of ≥15 and with dyspnoea on presentation. COVID-19 was confirmed to be a potential trigger of AD and ACLF. Respiratory failure frequently resulted in candidates being ineligible for LT and was the most frequent cause of death. During the two waves of the pandemic, clinical presentation, course and mortality risk from COVID-19 did not significantly change. Finally, short-term survival after LT was 96%, and no cases of SARS-CoV-2 reinfection were observed to date. In our analysis, liver transplant candidates with COVID-19 showed a 30-day mortality probability which was similar to that observed in a control group of cirrhotic patients hospitalised for AD due to bacterial infection. The overall mortality rate was 32.7% (37/113) and reached 49.2% (31/63) in patients with DC and a Lab-MELD score of >15, which is triple the mortality risk observed in listed patients with comparable Lab-MELD scores without COVID-19. 10 This indicates that liver Hepatology transplant candidates with DC should rigorously adopt all the usual measures to prevent SARS-CoV-2 infection and evidences the need for rapid implementation of reinforced vaccination programmes since the efficacy of standard vaccines will be likely lower than that reported in the registration studies. This is particularly relevant since the prevalence of COVID-19 in LT candidates was 6.05%, which is double that observed in the general population of similar age, 11 possibly due to higher susceptibility to SARS-CoV-2.

Despite the baseline Lab-MELD score being strongly associated with mortality, COVID-19-related respiratory failure remained the predominant cause of death at 89.2% (33/37), remaining at 10.2% (4/37) due to liver-related complications, these results concurring with previous studies from Europe and the USA. [12] [13] [14] [15] [16] [17] Following multivariable analysis, two factors, namely, dyspnoea on presentation and baseline Lab-MELD score emerged as independent predictors of mortality. Interestingly, patients listed for HCC had a much better outcome than those with DC, most likely because of associated lower Lab-MELD score at listing. The combination of Lab-MELD score of ≥15 and dyspnoea was associated with a negative prognosis, 60-day mortality risk of 68.8% (50.1-85.2), while any other possible combination of these two simple baseline factors allowed an early stratification of the mortality risk, and this may help clinicians in their decision-making. Despite what was observed in other patient cohorts, neither age nor comorbidities influenced the mortality risk, probably due to advanced age and increased comorbidities being exclusion criteria for WL.

COVID-19 led to a marked deterioration in liver function with high rates of AD (33.6%) and ACLF (17.6%) being observed. The occurrence of AD and ACLF in patients with COVID-19 was associated with a mortality risk of 59% and 90%, respectively, which compares unfavourably with the 44% and 65% observed by Marjot et al. 16 This finding is probably due to the different prevalence of patients with advanced liver impairment between the two cohorts (Child-Pugh B/C 76% vs 48%). We also compared our cases of ACLF occurring after COVID-19 with those observed in an appropriately balanced cohort of 91 cirrhotic patients who were admitted for AD triggered by bacterial infections. Notably, the mortality after developing ACLF was significantly higher for patients having ACLF triggered by COVID-19 (85% vs 53%), which is explained by the frequent occurrence of refractory respiratory failure in patients with COVID-19 and ACLF (18/20 vs 0/28).

A preliminary comparison between the two waves of the pandemic was possible. The 60-day mortality risk was 35.3% (95% CI 23.9% to 50.0%) during the first wave and did not significantly decline during the second wave (26%, 95% CI 16.2% to 40.2%), with respiratory failure remaining the major cause of death. This suggests that the impact of newly established therapies to control COVID-19 18 19 is limited in patients with advanced liver disease. Patients with prior COVID-19 had favourable outcomes, with early survival of 96% (25/26) after receiving a liver transplant. Median ICU and total hospital stay were 3 (IQR 3-6) and 11 days, which concur with what is observed in more recent series. 20 To date, zero case of SARS-CoV-2 recurrence was observed after LT.

Mortality in the great majority of patients in this cohort was due to respiratory failure (33/37, 89.2%), with respiratory failure being a clear contraindication for proceeding with an LT. Thus, apprehension related to wait-listed patients not receiving a graft for organ unavailability due to a decline in organ donation, and competition for ICU beds seems unfounded. Although, it cannot be excluded that a minority of urgent patients, SARS-CoV-2 negative, may have died on the WL due to a decline in organ offers, being indirect victims of the COVID-19 pandemic.

Two main limitations are to be acknowledged for this study. First, focusing on symptomatic cases with confirmed positive SARS-CoV-2 PCR test despite test sensitivity below 80%, we found that some cases may have inadvertently been excluded. Second, the impact of the COVID-19 pandemic on access to LT could not be measured.

In conclusion, liver transplant candidates with a MELD score of >15 and presenting with COVID-19-associated dyspnoea are at high risk of respiratory failure and early death. Once patients ACLF, acute-on-chronic liver failure; MELD, Model for End-stage Liver Disease.

Uncited Box 1 Centers participating to the ELITA/ELTR Covid-19 project in liver transplantation including all collaborators at each site Hepatology recover from COVID-19, LT is a safe option with no evidence of SARS-CoV-2 recurrence.

Department of Infectious Diseases Unit

Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology

Department of Surgery: Marco Zambelli, Michela Guizzetti and Michele Colledan. 4. Internal Medicine Unit of Treatment of Severe Organ Failure

Christophe Duvoux and Norbert Ngongang. 12. Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit: Sylvie Radenne, Domitille Poinsot and Celine Guichon; Department of Digestive Surgery and Liver Transplantation

Derek Manaz. 18. Hospital Clinic de Barcelona, General and Digestive Surgery Department

Hospital Universitari Vall D'Hebron, Liver Unit and HBP Surgery and Transplants Department

Liver Transplant Unit, Hospital Virgen del Rocio

Carmelo Loinaz. 26. Division of Transplantation, Department of General Surgery

Wojciech G. Polak; Department of Gastroenterology and Hepatology: Caroline den Hoed. 30. Department of Abdominal Surgery and Transplantation

Huddinge Hospital, Department of Transplantation Surgery

Department of General, Transplant and Liver Surgery

Cirrhosis as a risk factor for sepsis and death: analysis of the National hospital discharge survey

Bacterial infections in cirrhosis: a position statement based on the EASL special conference

Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide

Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance

Acute-On-Chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis

Bacterial and fungal infections in acuteon-chronic liver failure: prevalence, characteristics and impact on prognosis

A/H1N1/09 influenza is associated with high mortality in liver cirrhosis

Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

Improving liver allocation: MELD and PelD

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience

Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Liver transplant length of stay (Los) index: a novel predictive score for hospital length of stay following liver transplantation

The authors thank the European Liver and Intestine Association board members: Ulrich Baumann, Giacomo Germani, Silvio Nadalin, Pavel Taimr, Christian Toso and Krzysztof Zieniewicz for supporting and actively promoting the study; Maruska C Nizzi for linguistic support; and all centres participating in the ELITA/ELTR COVID-19 project in liver transplantation, including all collaborators ateach site (box 1). 

 1 Hepatology and Gastroenterology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy 2 Hepatology, Hopital Henri Mondor, Creteil, France Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Competing interests None declared.

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Ethics approval Ethical approval was given by clinical research ethics committee from Hospital Clinic Barcelona (ID: HCB/2020/0479). This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.